The effect of curcumin supplementaion on clinical symptoms , acute phase reactants and inflamatory cytokines in patients with covid-19 hospitalization

INTERVENTION: Intervention 1: Intervention group: They receive 4 capsules of curcumin 40 mg daily made by Elixir Nano Drug Company for 14 days. Intervention 2: Control group: receive 4 placebo daily for 14 days. CONDITION: covid‐19. PRIMARY OUTCOME: Albumin, ferritin,CRP, ESR, interleukin 6,WBC,total lymphocyte count(TLC) Alanine Aminotransferase(ALT)(ALT),Aspartate Amino transferase(AST),LDH, resperatory oxygen saturation (SpO2) Nutritional Risk Index (NRI). Timepoint: The first day of study, the fourteenth day of study. Method of measurement: Blood test, Nutritional Risk Index questionnaire. INCLUSION CRITERIA: They have a positive PCR test or lung involvement in the imaging and 2‐ Hospitalized patients who are non‐intubated. 3‐ They are over 18 years old .4‐ They have filled in the informed consent form5. 5‐They are not pregnant or breastfeeding.6‐They do not have gallbladder inflammation or active gastrointestinal ulcers.7. They do not have hemophilia or coagulation disease.8‐ renal failure with GFR <30 ml / min or dialysis patients.9‐ Signing informed written consent.10. Not participating in other clinical trials at the same time 11.cancer patients